Atlas Venture Portfolio 2026

23 companies backed by Atlas Venture, including Scorpion Therapeutics, Be Biopharma, Antares Therapeutics. Each links to its full verified cap-table syndicate.

Atlas Venture accounts for 64 tracked companies with verified cap-table data, 64 of which disclose round sizes totalling $13B. The median disclosed raise is $132M, and the largest is Kailera Therapeutics at $1.6B, ahead of DataRobot ($1.1B) and ACELYRIN ($758M).

The names that recur most often on these portfolio cap tables are Atlas Venture (64 companies), OrbiMed (9 companies), RA Capital Management (9 companies), 5AM Ventures (8 companies), Alexandria Venture Investments (7 companies), Access Biotechnology (6 companies). By latest disclosed round, the market skews Series A (22), Series B (18), Series C (10), IPO (3).

Best funded Atlas Venture companies

  1. Kailera Therapeutics — $1.6B (latest: IPO)
  2. DataRobot — $1.1B (latest: Series G)
  3. ACELYRIN — $758M (latest: Series C)
  4. Nimbus Therapeutics — $600M (latest: Series B)
  5. Hopper — $600M (latest: Series G)
  6. Scorpion Therapeutics — $515M (latest: Series D)
  7. Vigil Neuroscience — $350M (latest: IPO)
  8. Endeavor BioMedicines — $292M (latest: Series A)
  9. Triveni Bio — $277M (latest: Series C)
  10. Diagonal Therapeutics — $253M (latest: Series B)
  11. Mariana Oncology — $250M (latest: Series B)
  12. Spero Therapeutics — $250M (latest: Series A)
  13. Aiolos Bio — $245M (latest: Series A)
  14. Escient Pharmaceuticals — $238M (latest: Series C)
  15. Triana Biomedicines — $230M (latest: Series A)

Atlas Venture — related firms and companies (56)

Atlas Venture profile · All research reports